Real-world Clinical Outcomes of NSCLC Patients Receiving Neoadjuvant Immunotherapy

Recruiting now

Conditions studied: NSCLC

In brief

The goal of this observational study is to evaluate the efficacy and long-term clinical outcomes of different neoadjuvant immunotherapies in non-small cell lung cancer (NSCLC) patients using the real-world data. The main questions it aims to answer are: * What the best setting for immune checkpoint inhibitors as the neoadjuvant treatment? * How to determine the subgroups of patients benefit from neoadjuvant immunotherapy? Participants will receive neoadjuvant immunotherapy the study will analyze the real-world data.

Key facts

Study ID

NCT06317558

Run by

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

People needed

4000

Starts

2024-03-01

Expected to finish

2034-12-31

Last updated by the study team

2024-07-03

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histological diagnosis of non-small cell lung cancer (Stage I-IV, International Association for the Study of Lung Cancer staging eighth edition)
• Patients who have previously undergone immune checkpoint inhibitors as the neoadjuvant treatment;
• No previous history of malignant tumors and other malignant tumors at the same time, without any anti-tumor treatment;
• Eastern Cooperative Oncology Group (ECOG) score 0-1, heart, lung, liver, brain and kidney function can tolerate surgery;
• At least one measurable lesion (RECIST v1.1).

You may not qualify if…

• Patients included in unblinded clinical trials or anti-tumor drug intervention.
• Radiotherapy or systemic therapy were used for NSCLC patients before the surgery.

Where it is running

• Shugeng Gao — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.